A new multiple myeloma cell line, MEF‐1, possesses cyclin d1 overexpression and the p53 mutation

• Published in: Cancer 1999-04, Vol.85 (8), p.1750-1757
• Main Authors: Yufu, Yuji, Goto, Tatsuro, Choi, Ilseung, Uike, Naokuni, Kozuru, Mitsuo, Ohshima, Koichi, Taniguchi, Toshiyasu, Motokura, Toru, Yatabe, Yasushi, Nakamura, Shigeo
• Format: Article
• Language: English
• Subjects: Aged; Bone Marrow; Bone Marrow - pathology; Bone Neoplasms - genetics; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; cell line; Chromosomes, Human, Pair 11 - genetics; Chromosomes, Human, Pair 11 - ultrastructure; Chromosomes, Human, Pair 14 - genetics; Chromosomes, Human, Pair 14 - ultrastructure; cyclin D1; Cyclin D1 - biosynthesis; Cyclin D1 - genetics; Epstein-Barr Virus Infections - genetics; Epstein-Barr Virus Infections - metabolism; Epstein-Barr Virus Infections - pathology; Fatal Outcome; Female; Forearm; Gene Expression Regulation, Neoplastic; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, p53; Herpesvirus 4, Human - isolation & purification; Humans; Immunophenotyping; Karyotyping; multiple myeloma; Multiple Myeloma - genetics; Multiple Myeloma - metabolism; Multiple Myeloma - pathology; Multiple Myeloma - virology; Myeloma Proteins - genetics; Neoplasm Proteins - biosynthesis; Neoplasm Proteins - genetics; p53; Polymorphism, Single-Stranded Conformational; t(11,14)(q13,q32); Translocation, Genetic; Tumor Cells, Cultured - metabolism; Tumor Cells, Cultured - virology
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/(SICI)1097-0142(19990415)85:8<1750::AID-CNCR15>3.0.CO;2-5

BACKGROUND The t(11;14)(q13;q32) translocation with cyclin D1 overexpression commonly is found in multiple myeloma (MM) and in mantle cell lymphoma (MCL). Several reports have shown that p53 mutations in MCL lead to blastoid transformation and a worse prognosis; however, the role of p53 mutations in MM with t(11;14) is unclear. METHODS In this study the authors describe a patient with MM with t(11;14) and a p53 mutation at presentation and characterized a cell line, MEF‐1, established from this patient. Immunohistochemical analysis of p53 and cyclin D1 proteins was performed. The p53 gene was analyzed by polymerase chain reaction‐single strand conformation polymorphism and direct sequencing. The expression of cyclin D1 mRNA was examined by Northern blot analysis. RESULTS MEF‐1 had t(11;14) with overexpression of cyclin D1 mRNA and produced immunoglobulin κ‐light chain. MEF‐1 had a mutation in exon 7 (codon 255–257) of the p53 gene, which was noted in the patient's myeloma cells. CONCLUSIONS p53 mutations may be important genetic events in disease progression of MM with t(11;14). The MEF‐1 cell line may be a useful tool to study mechanisms of progression in MM based on abnormalities of the cyclin D1 gene. Cancer 1999;85:1750–7. © 1999 American Cancer Society. In the current study the authors established a new myeloma cell line with t(11;14)(q13;q32) and a mutation in the p53 gene. p53 mutations correlate with cyclin D1 overexpression not only in mantle cell lymphoma, but also in multiple myeloma with t(11;14).